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At the 16th Annual American College of Cardiology Con•
ference held in Snowmass, Colorado in January 1985, a 
series of papers was presented on the current results of valve 
surgery. The presenters were Drs. Albert Starr, Alain Car•
pentier, Viking Bjork, Marian Ionescu, Karl Victor Hall, 
Jack Matloff, John ReIland and John Callaghan, a group of 
surgeons whose combined experience with the development 
of new valves and their subsequent advancement into world•
wide cardiac surgical practice is unequaled. 
The occasion provided an opportunity not only to create 
some order out of the confusing, rapidly proliferating array 
of valve choices, but also to reflect on how far we have 
come in the first quarter century of valve replacement. Thou•
sands of closed valve operations had been performed before 
the first valve was replaced because replacement had to await 
the perfecting of cardiopulmonary bypass. After John Gib•
bon's first "pump" operation in October 1953 the repair of 
all cardiac defects became possible. But prosthetic valves 
still had to be developed. 
Development of valve prostheses. Dr. Charles Huf•
nagel implanted caged ball valves and Dr. Gordon Murray 
sewed homo grafts into the descending aorta for the treatment 
of aortic regurgitation in the mid 1950s. These operations 
partially corrected the physiologic problems, but were not 
true valve replacements. 
Dr. Albert Starr first replaced the mitral valve on the 
21 st of September 1960 (1). He was not alone in working 
on the problems of valve replacement. Bahnson, Binet, 
Bjork, Beall, Barratt-Boyes, Carpentier, Harken, lonescu, 
Kay, Ross, Smeloff and many others contributed new de•
signs and techniques, expanding the frontiers of cardiac 
surgery. 
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That first exciting decade brought forth a flood of designs: 
ball valves, "toilet seats," butterfly flaps, single cusps and 
whole valves imitating the aortic valve; prostheses with 
round poppets, cone-shaped poppets and discs of various 
thicknesses made with a multitude of materials. Stellite, 
Teflon as a woven cloth or as a solid poppet, delrin, titanium 
pyrolite carbon, Silastic rubber and polypropylene are but 
a few of those materials. And, at the same time, tissue 
valves, homografts and xenografts were used with increas•
ing success. The successful 23 year results of Barratt-Boyes 
(personal communication, \985) with fresh homografts at•
test to the validity of this concept. 
The lack of regulation by the Food aQd Drug Adminis•
tration in this era made it possible to redesign and try out 
valves quickly. There are those who believe that if the 
present stringent regulations governing valve development 
had been in force we would be many years behind our 
present position, although there were probably many pa•
tients who paid with their lives in return for rapid advances 
for others. 
As complications became apparent, new designs were 
soon produced in an attempt to obviate newfound problems. 
Struts wt!re covered with cloth so that clots would adhere 
to the cloth and a protective neo-intima would smooth over 
the interstices of the weave. But the wear and tear of a 
million beats every 6 weeks in the strange and destructive 
environment of the bloodstream broke down the cloth and 
caused new problems. 
Soft discs were eroded by the struts but hard discs eroded 
the struts, so the materials were changed again. Pyrolite 
carbon, a space age material said to be second only to 
diamonds in hardness, was substituted for the softer plastics 
and Silastic. But, in the meantime, it became apparent that 
two early Silastic ball valves, the Starr valve (model 1200) 
and the Smeloff valve could withstand the stresses of pro•
longed use and did not have to be changed. 
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Complications. Not long after the first valves were im•
planted in patients complications began to appear. Some of 
these had been anticipated; others had not. It was realized 
from the start that patients would have to take anticoagulant 
agents, but the possibilities of mechanical changes had not 
been fully realized, although extensive bench testing had 
been done. Bench testing was no substitute for in vivo 
experiments. Few dogs survived valve replacement, usually 
because the valve clotted in the first few weeks. Pigs, sheep 
and calves became the experimental animals because it was 
believed that their vascular systems or coagulation processes 
more closely approximate those of humans. Primates were 
too expensive. 
Thromboembolism, thrombosis without embolism, par•
avalvular leakage, hemolysis, poppet embolism, ball vari•
ance, infection, cusp rupture and degradation, valve stenosis 
and functional gradients: the list of problems is long and 
not yet complete. But gradually, with changes in materials 
and design, the problems have become fewer, although they 
have not disappeared. Some will never disappear. Bacterial 
endocarditis is not primarily a problem of valve design, but 
perhaps its incidence can be reduced by constant vigilance. 
The same vigilance can reduce the complications of 
anticoagulants. 
An outsider looking at this history might conclude that 
it is an account of meddlesome physicians experimenting 
without regard for the consequences. Nothing could be fur•
ther from the truth. The amount of research, the dollars, 
time, effort and concern that have gone into the development 
of valves now available have been enormous. Perhaps the 
pace of changes has slowed, and rightly so. Cardiologists 
and surgeons have before them a choice of many good val ves 
that have stood the tests of time and use. The urge and need 
for new designs is not as great as it was 10 or 20 years ago. 
The federal government has entered the fray, imposing reg•
ulations to guarantee that everything produced will, as nearly 
as possible, be free of problems. 
Present status of prosthetic valves. The ultimate test 
of a valve has always been long-term survival of patients 
using the valve. As the years go by, the concept of "long 
term" itself changes. In the first few years reports described 
I and 2 year results. Then a few 5 year results appeared. 
And now we are in a position to look for a small number 
of 20 year results, many 10 year results and hundreds of 5 
year results. Analyzing such long-term results introduces 
new problems. During the years under study the selection 
of patients, surgical techniques and skills and those unde•
finable changes that occur as surgeons become more ex•
perienced have been in a state of constant flux. Starr (2) 
has clearly demonstrated in his paper published in this issue 
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that among his patients the results have improved in different 
time periods even though the operations they received were 
ostensibly the same. 
We may never have definitive results. At best, we may 
be able to say to patients, "Here and now, with this valve, 
at your age and with your ventricular function, you have a 
certain percent chance of living 5 years, a different chance 
of living 10 years, and your chances of living without any 
complications are such and such. With your new valve you 
may have problems but we hope that the problems you have 
will be less serious than the problems you have had. " 
The papers presented in this and subsequent issues review 
the results with several valves. Some of the results presented 
cover many years, others only a few years; but, taken in 
toto, they represent a spectrum of choices now available to 
physicians and patients. Twenty-five years ago most of us 
thought that within a quarter century the major problems 
would be solved and we would have the "perfect" valve. 
That dream has not materialized and, more realistically, we 
now recognize that there is no perfect valve. Different pa•
tients have different needs. We need choices. The valve 
that is best for a 40 year old man with a sedentary job may 
not be best for a 70 year old woman who lives by herself 
and whose memory is not what it once was. The best valve 
for a child is not the best for all adults. 
"The patient-valve interface index." But how is the 
clinician to choose what is best? Perhaps from this series 
of papers can be developed a patient-valve interface index. 
Such an index would take into account the many factors 
relevant to choice of a valve, such as clinical and laboratory 
data, immunologic and hematologic data, associated ill•
nesses, potential pregnancy, age, job, activity level, body 
size, ability to take anticoagulants, psychologic status, and 
so on, assigning to each factor a numerical weight. These 
values could then be correlated with what is known about 
the performance profile of the different valves available. 
The final index would then indicate which valve or valves 
would be the best choices for that particular patient. Ulti•
mately, the choice should be a joint decision involving the 
surgeon, the cardiologist and a well informed patient. What•
ever changes there may be in the next quarter century, it is 
to be hoped that the procedure for choosing a valve for a 
particular patient will become more logical, resulting in the 
best of possible long-term results. 
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